A phase I clinical and pharmacokinetic study of the camptothecin glycoconjugate, BAY 38-3441, as a daily infusion in patients with advanced solid tumors.
Mross K, Richly H, Schleucher N, Korfee S, Tewes M, Scheulen ME, Seeber S, Beinert T, Schweigert M, Sauer U, Unger C, Behringer D, Brendel E, Haase CG, Voliotis D, Strumberg D.
Mross K, et al. Among authors: unger c.
Ann Oncol. 2004 Aug;15(8):1284-94. doi: 10.1093/annonc/mdh313.
Ann Oncol. 2004.
PMID: 15277271
Free article.
Clinical Trial.